The Contact-Hitting R&D Strategy of Family Firms in the Japanese Pharmaceutical Industry

Shigeru Asaba*, Tetsuo Wada

*この研究の対応する著者

研究成果: Article査読

2 被引用数 (Scopus)

抄録

This article addresses the following question: How do family firms investing less in research and development (R&D) than nonfamily firms compete in R&D intensive industries? Using Japanese pharmaceutical industry data, we found that family firms produce more patents per R&D than nonfamily firms but are not biased toward low-value innovations. Further analyses of the distribution over innovation value suggested that family firms adopt a “contact-hitting R&D strategy,” avoiding radical innovations and pursuing incremental innovations compatible with their signature moves: innovation through tradition and narrow and internal search and resulting in may low-value innovations and a few mid or high-value innovations.

本文言語English
ページ(範囲)277-295
ページ数19
ジャーナルFamily Business Review
32
3
DOI
出版ステータスPublished - 2019 9 1

ASJC Scopus subject areas

  • ビジネス、管理および会計(その他)
  • 財務

フィンガープリント

「The Contact-Hitting R&D Strategy of Family Firms in the Japanese Pharmaceutical Industry」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル